We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Significant Nail in the Coffin for Jacobus’ LEMS Treatment Ruzurgi
Significant Nail in the Coffin for Jacobus’ LEMS Treatment Ruzurgi
It appears the end has come for Jacobus Pharmaceutical’s Ruzurgi, a potassium channel blocker that had received an Orphan Drug designation from the FDA for treatment of Lambert-Eaton myasthenic syndrome (LEMS) in children age six to 16, but had yet to be approved.